⁃ All participants with or without diabetes:

• Have a Body Mass Index (BMI) ≥27 kilogram/square meter (kg/m²) at screening

• Diagnosed with chronic kidney disease (CKD)

• Has an estimated glomerular filtration rate (eGFR) ≥25 to ≤60 ml/min/1.73 m² or eGFR ≥25 to ≤75 ml/min/1.73 m² if urine albumin-to-creatinine ratio (UACR) \>30 milligram/gram (mg/g)

• Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension)

⁃ Participants without diabetes:

• Have Hemoglobin A1c (HbA1c) \<6.5% at screening

⁃ Participants with Type 2 diabetes:

• Have been diagnosed at least 180 days prior to screening

• Have HbA1c ≤9.5% at screening